Recent Quotes (30 days)

You have no recent quotes
chg | %

Response Biomedical Corp  

(Public, TSE:RBM)   Watch this stock  
Find more results for RBM
0.000 (0.00%)
May 24 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range     -
52 week 0.34 - 1.00
Open     -
Vol / Avg. 0.00/1,773.00
Mkt cap 8.73M
P/E     -
Div/yield     -
EPS -0.03
Shares 9.93M
Beta 2.74
Inst. own     -
Aug 12, 2016
Q2 2016 Response Biomedical Corp Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 13, 2016
Response Biomedical Corp Annual Shareholders Meeting - 2:00PM EDT - Add to calendar
May 18, 2016
Response Biomedical Corp Annual Shareholders Meeting (Estimated)
May 16, 2016
Q1 2016 Response Biomedical Corp Earnings Release
Mar 22, 2016
Q4 2015 Response Biomedical Corp Earnings Release

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -56.72% -0.97%
Operating margin -35.93% 1.85%
EBITD margin - 8.35%
Return on average assets -46.15% -1.18%
Return on average equity - -
Employees 65 -
CDP Score - -


1781 75th Ave W
+1-604-4566010 (Phone)
+1-604-4566066 (Fax)

Website links


Response Biomedical Corp. (Response) offers diagnostic technologies for the medical central-lab testing, point of care (POC) testing and on-site environmental testing markets. The Company operates through the research, development, commercialization and distribution of diagnostic technologies segment. The Company develops, manufactures and sells its RAMP system for the global medical point of care market, including cardiovascular testing, infectious disease testing market and the on-site environmental testing market, including biodefense and vector environmental testing. In the United States, its RAMP 200 Reader is limited to central-lab use with the cardiovascular tests. POC, on-site diagnostic tests (or assays) are non-laboratory-based tests performed using portable hand-held devices, compact desktop analyzers, single-use test cartridges and/or dipsticks. The Company's RAMP system is a platform technology that combines a fluorescence detection system with lateral flow immunoassays.

Officers and directors

Barbara R. Kinnaird Ph.D. Chief Executive Officer, Director
Age: 48
William J. Adams Chief Financial Officer, Secretary
Age: 53
Lewis J. Shuster Chairman of the Board
Age: 60
Anthony F. Holler M.D. Director
Age: 63
Peter A. Thompson M.D. Director
Age: 56
Jonathan J. Wang Ph.D. Director
Age: 47
Joseph D. Keegan Ph.D. Independent Director
Age: 61
Clinton H. Severson Independent Director
Age: 67